Kalaris Therapeutics (KLRS) Common Equity (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Common Equity of $68.6 million for Q1 2026, up 7.33% year-over-year from $63.9 million in Q1 2025, and down 13.01% quarter-over-quarter from $78.8 million in Q4 2025.
Kalaris Therapeutics (KLRS) Common Equity (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $68.6 million for Q1 2026.
- In Q1 2026, Common Equity rose 7.33% year-over-year to $68.6 million; the TTM figure through Mar 2026 stood at $68.6 million (up 7.33% YoY), while the FY2025 annual figure was $78.8 million, up 181.57% from the prior year.
- Common Equity for Q1 2026 stood at $68.6 million, down from $78.8 million in the prior quarter.
- The five-year high for Common Equity was $253.2 million in Q3 2022, with the low at -$96.6 million in Q4 2024.
- The 5-year median for Common Equity is $68.6 million (2026), against an average of $83.6 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity sank 145.76% in 2024, then soared 234.36% in 2025.
- Kalaris Therapeutics' Common Equity stood at $224.5 million in 2022, then plunged by 120.05% to -$45.0 million in 2023, then sank by 114.62% to -$96.6 million in 2024, then jumped by 181.57% to $78.8 million in 2025, then slipped by 13.01% to $68.6 million in 2026.
- Business Quant data shows KLRS's Common Equity at $68.6 million in Q1 2026, $78.8 million in Q4 2025, and $41.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 9.79 Bn |
| 10 | Kalaris Therapeutics | 99.71 Mn | 99.71 Mn | - | 57.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.67 Mn |
| Mar 31, 2026 | 68.56 Mn |
| Dec 31, 2025 | 78.81 Mn |
| Sep 30, 2025 | 41.87 Mn |
| Jun 30, 2025 | 53.12 Mn |
| Mar 31, 2025 | 63.87 Mn |
| Dec 31, 2024 | -96.62 Mn |
| Sep 30, 2024 | -89.38 Mn |
| Jun 30, 2024 | -51.53 Mn |
| Mar 31, 2024 | -47.54 Mn |
| Dec 31, 2023 | -45.02 Mn |
| Sep 30, 2023 | 195.33 Mn |
| Jun 30, 2023 | 229.11 Mn |
| Mar 31, 2023 | 193.53 Mn |
| Dec 31, 2022 | 224.52 Mn |
| Sep 30, 2022 | 253.23 Mn |
| Jun 30, 2022 | 158.14 Mn |
| Mar 31, 2022 | 191.68 Mn |
| Dec 31, 2021 | 225.27 Mn |
| Sep 30, 2021 | 267.30 Mn |